Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse
September 13, 2024
Supplementary Data 1 Legend from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Data legend for supplementary data 1, showing the process chart and raw whole slide images of multiplex IHC.